International Clinical Psychopharmacology
April 23, 2021
Kyle T. Greenway, Nicolas Garel, Nathalie Goyette et al.
12 citations
Intravenous ketamine is an effective treatment of bipolar depression. One of its most important side-effects is a transient altered state of consciousness commonly referred to as dissociation. These states can be anxiety-provoking, distressing and even treatment-limiting, warranting research into mitigation strategies. In this article, we present two cases that demonstrate the potential of...
International Journal of Cognitive Therapy
April 20, 2021
Emilee E. Burgess, Steven Selchen, Benjamin D. Diplock et al.
Mindfulness-based interventions (MBIs) have emerged as clinically effective interventions for anxiety and depression although there are significant barriers to their access in the general population. The present study examined the effectiveness of a 5-week abbreviated mindfulness-based cognitive therapy (MBCT) intervention for a physician-referred, treatment-seeking, community sample (N = 54)...
Journal of Psychoactive Drugs
April 20, 2021
M. Earleywine, Brianna R. Altman, Joseph A. de Leo
8 citations
ABSTRACT Ketamine, a novel treatment for depression, has generated considerable interest and research. Few experiments address lay impressions of the credibility of ketamine treatment relative to another popular intervention for depression, CBT. Over 500 participants with depressive symptoms read descriptions of CBT, ketamine, and a treatment that combined the two. Descriptions included pros...
Brazilian Journal of Health Review
April 19, 2021
Giovanni Pereira Pio, Aline Moreira Vitorino, Naira Braga Aidar et al.
2 citations
Introdução: A depressão é um transtorno psiquiátrico caracterizado por episódios agudos ou recorrentes de humor deprimido e perda de interesse ou prazer, levando a prejuízos funcionais ao paciente. A psilocibina é uma droga psicodélica com propriedades alucinógenas e serotoninérgicas derivada de cogumelos do gênero Psilocybe. Estudos recentes demonstram potenciais efeitos terapêuticos dessa...
Frontiers in Pharmacology
April 15, 2021
Meiying Cui, Wanlin Dai, Jing Kong et al.
43 citations
Background: Major depressive disorder is associated with inflammation and immune processes. Depressive symptoms correlate with inflammatory markers and alterations in the immune system including cytokine levels and immune cell function. Th17 cells are a T cell subset which exerts proinflammatory effects. Th17 cell accumulation and Th17/Treg imbalances have been reported to be critical in the...
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
April 15, 2021
Dave Nichols
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a...
New England Journal of Medicine
April 14, 2021
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts et al.
1,372 citations
On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are...
Frontiers in Psychology
April 12, 2021
Henriette Löffler-stastka, Kathrin Bednar, Ingrid Pleschberger et al.
Depression has been widely studied by researchers from different fields, but its causes, and mechanism of action are still not clear. A difficulty emerges from the shifting from objective diagnosis or analysis to exploration of subjective feelings and experiences that influence the individuals' expression, communication and coping in facing depression. The integration of the experiential...
medRxiv
April 7, 2021
David E. Gard, Mollie Pleet, Ellen Bradley et al.
preprint
Abstract Objective: Given the treatment limitations of depression in bipolar disorder, we evaluated the known risks of using psilocybin (and similar substances) in this population, including a systematic assessment of published case histories, to assess the risk of psilocybin as a treatment of depression in bipolar disorder. Data Sources: A comprehensive search of case studies published through...
Clinical Case Reports
April 4, 2021
Terry Schwartz, Mary Ellen Trunko, David Feifel et al.
52 citations
Abstract Severe and enduring eating disorders (EDs) have the highest mortality rate of all psychiatric illnesses (Arch Gen Psychiatry, 2011, 68 , 724), especially when comorbid with treatment‐resistant depression (TRD) (Psychiatr Res, 2016, 244 , 45). We report on four patients with enduring EDs and TRD treated with repeat ketamine over 12 + months, showing improvement in depression with only...
Biological Psychiatry Global Open Science
April 1, 2021
Yujing Zhang, Bing Xie, Yin Yuan et al.
Background Poststroke social isolation could worsen poststroke depression and dampen neurogenesis. (R,S)-ketamine has antidepressant and neuroprotective effects; however, its roles and mechanisms in social isolation–mediated depressive-like behaviors and sensorimotor recovery remain unclear. Methods Mice were subjected to transient middle cerebral artery occlusion, and then were pair-housed...
European Psychiatry
April 1, 2021
M. Trigo
Introduction Depression is one of the most prevalent mental illnesses, leading to important personal distress and economic consequences. Treatment is long, often involving psychotherapy and pharmacological treatment, and relapses are frequent. Used mostly for treatment of mood disorders and alcohol dependence, drugs such as lysergic acid diethylamide (LSD) were studied in the 1950’s and showed...
The Journal of family practice
April 1, 2021
Amanda Zorn, Sean Linn, Mat Jenkinson et al.
5 citations
MAYBE, but it's too soon to tell. There is limited evidence that ketamine by itself is effective in the very short term. Single-dose intravenous (IV) ketamine is more likely than placebo (odds ratio = 11-13) to produce improvement (> 50%) in standardized depression scores in 1 to 3 days, lasting up to a week. Twice- or thriceweekly IV ketamine improves symptom scores by 20%-25% over 2 weeks...
CNS Spectrums
April 1, 2021
Steve Best, Dan G. Pavel, Natalie Haustrup
1 citation
AbstractBackgroundRepetitive transcranial magnetic stimulation (rTMS) is a safe, effective and non-invasive treatment for many psychiatric illnesses, including treatment-resistant depression (TRD). Ketamine, an NMDA receptor antagonist, is also an effective antidepressant. This retrospective review examined the clinical benefits of combining these two established treatments for patients...
European Psychiatry
April 1, 2021
A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira et al.
1 citation
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression (TRD). Novel antidepressants with rapid and sustained effects on mood and cognition could...
Advanced Biomedical Research
March 29, 2021
Fatemeh Zargar, Leila Rahafrouz, Mohammad Javad Tarrahi
Background: Patients with somatic symptom disorder (SSD) had a poor quality of life and suffered from depression, anxiety, and stress. Mindfulness-based stress reduction (MBSR) is a psychological treatment with remarkable effects on several psychological disorders. This study aimed to evaluate the effect of the MBSR program on psychological symptoms, quality of life, and symptom severity in...
The Open Public Health Journal
March 22, 2021
Ormanee Patarathipakorn, Manyat Ruchiwit, Marlaine Smith
Background: The increased amount of depression among people with diabetes is a burden on society. Biofeedback and meditation can impact the self-regulation of this group. Objective: This study aims to study the effect of combining meditation with a biofeedback training program on the stress and depression among diabetes people with mild depression. Methods: This study is based on a randomized...
Frontiers in Psychology
March 22, 2021
Mohamed Al-Refae, Amr Al-Refae, Melanie Munroe et al.
Introduction: Many individuals and families are currently experiencing a high level of COVID-19-related stress and are struggling to find helpful coping mechanisms. Mindfulness-based interventions are becoming an increasingly popular treatment for individuals experiencing depression and chronic levels of stress. The app (Serene) draws from scholarly evidence on the efficacy of mindfulness...
BMC Neurology
March 21, 2021
Torsten Sauder, Philipp M Keune, Roy Müller et al.
Abstract Objectives Persons with MS (PwMS) often display symptoms of depression and fatigue. Mindfulness-based interventions are known to counteract these symptoms. However, to-date the exact relations between trait mindfulness, depression and fatigue remain to be examined. Fatigue is generally regarded as a symptom immanent to the disease and as a direct neurobiological consequence of...
Religions
March 21, 2021
Ngar-sze Lau
This paper examines how the teaching of embodied practices of transnational Buddhist meditation has been designated for healing depression explicitly in contemporary Chinese Buddhist communities with the influences of Buddhist modernism in Southeast Asia and globalization. Despite the revival of traditional Chan school meditation practices since the Open Policy, various transnational lay...